State Street SPDR S&P Biotech ETF
700 hedge funds and large institutions have $7.55B invested in State Street SPDR S&P Biotech ETF in 2021 Q4 according to their latest regulatory filings, with 140 funds opening new positions, 210 increasing their positions, 198 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
5% less capital invested
Capital invested by funds: $7.94B → $7.55B (-$387M)
5.63% less ownership
Funds ownership: 111.04% → 105.42% (-5.6%)
21% less call options, than puts
Call options by funds: $2.63B | Put options by funds: $3.35B
Holders
700
Holding in Top 10
20
Calls
$2.63B
Puts
$3.35B
Top Buyers
| 1 | +$265M | |
| 2 | +$211M | |
| 3 | +$181M | |
| 4 |
MCM
Moore Capital Management
New York
|
+$161M |
| 5 |
Goldman Sachs
New York
|
+$148M |
Top Sellers
| 1 | -$492M | |
| 2 | -$292M | |
| 3 | -$238M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$197M |
| 5 |
CAC
Cowen and Company
New York
|
-$50.3M |